Long-Read Sequencing of Structural Variants in Human Connective Tissue Disorders

Abstract

Structural variants are an important but historically underrecognized cause of human connective tissue disorders. Deletions, duplications, inversions, translocations, repeat expansions, mobile-element insertions, and complex rearrangements can disrupt extracellular matrix genes, alter regulatory architecture, or produce abnormal dosage of proteins involved in collagen biology, vascular integrity, skeletal development, and tissue repair. Conventional short-read sequencing and targeted assays frequently fail to resolve these changes because of repetitive DNA, homologous sequences, large rearrangements, and incomplete representation of breakpoint structure. Long-read sequencing provides extended contiguous reads that can span repetitive regions, connect distant breakpoints, phase variants with nearby single-nucleotide changes, and characterize complex alleles more accurately. This review examines the clinical rationale, disease burden, pathophysiology, risk factors, diagnostic applications, management implications, emerging technologies, and guideline considerations associated with long-read sequencing in connective tissue disorders. Particular attention is given to heritable aortopathies, Ehlers-Danlos syndromes, osteogenesis imperfecta, Marfan-spectrum disorders, and syndromic skeletal dysplasias. Although challenges remain regarding cost, analytical standardization, variant interpretation, and equitable access, long-read sequencing is increasingly relevant to unresolved cases and may support more precise diagnosis, family counseling, surveillance, and future genotype-directed care.

Introduction

Human connective tissue disorders comprise a diverse group of inherited conditions affecting collagen, elastin, fibrillin, proteoglycans, basement membranes, and related cellular pathways. Their clinical expression ranges from joint hypermobility and skin fragility to progressive aortic aneurysm, arterial dissection, skeletal deformity, ocular complications, pulmonary disease, and substantial disability. Molecular diagnosis is clinically valuable because it can refine prognosis, guide organ surveillance, inform treatment, and identify relatives who require preventive evaluation.

Most diagnostic workflows begin with phenotype-directed panels, exome sequencing, or genome sequencing performed with short-read platforms. These approaches detect many single-nucleotide variants and small insertions or deletions, but their ability to identify structural variation is variable. Breakpoints located in repetitive elements, duplicated genomic segments, or regions with high sequence similarity may be missed or inaccurately mapped. Long-read sequencing addresses this limitation by generating reads that may extend across complete genes, introns, repetitive segments, and rearrangement junctions. Both single-molecule real-time and nanopore-based platforms can contribute to structural variant discovery, although their performance characteristics, error profiles, and analytic pipelines differ.

Epidemiology / Disease Burden

Connective tissue disorders are individually uncommon but collectively represent a significant burden in genetics, cardiology, orthopedics, rheumatology, ophthalmology, and vascular medicine. Heritable thoracic aortic disease may arise from pathogenic variants in genes encoding extracellular matrix proteins, smooth-muscle contractile components, transforming growth factor beta pathway members, or regulators of vascular development. Ehlers-Danlos syndromes include multiple molecularly distinct subtypes, some of which are associated with severe vascular complications. Osteogenesis imperfecta and related bone fragility disorders are frequently caused by collagen pathway abnormalities, but atypical phenotypes and unresolved cases remain clinically important.

The true contribution of structural variants is difficult to quantify because older studies used assays with limited sensitivity for large or complex rearrangements. In diagnostic cohorts, copy-number changes and exon-level deletions or duplications account for a meaningful proportion of pathogenic findings in several inherited disease categories. Long-read studies have additionally demonstrated that some apparently negative genomes contain inversions, repeat-mediated rearrangements, deep intronic changes, or complex alleles that are not readily detected by conventional methods. The burden is therefore not limited to molecular uncertainty; delayed diagnosis can postpone cardiovascular surveillance, fracture prevention, surgical planning, and counseling regarding recurrence risk.

Pathophysiology

Structural variants can cause disease through several mechanisms. A deletion may remove one or more exons, produce haploinsufficiency, or eliminate a regulatory element required for tissue-specific expression. Duplications can increase gene dosage or disrupt reading frame when joined to an unrelated sequence. Inversions may interrupt coding regions or separate promoters from their target genes. Translocations and complex rearrangements can create fusion transcripts, alter chromatin organization, or reposition enhancers. Repeat expansions and mobile-element insertions may interfere with transcription, RNA processing, or genome stability.

In connective tissue disorders, these mechanisms affect the composition and organization of the extracellular matrix. Abnormal collagen synthesis or folding weakens bone, tendon, ligament, skin, and vascular walls. Impaired fibrillin microfibril assembly alters elastic fiber function and can dysregulate transforming growth factor beta signaling. Defects in basement membrane proteins compromise tissue barriers, while disruptions in smooth-muscle or cytoskeletal genes can reduce arterial resilience. Long-read sequencing is particularly valuable when pathogenicity depends on the exact architecture of an allele, because a sequence-spanning read can establish whether a rearrangement removes coding sequence, preserves an in-frame segment, or creates a clinically relevant fusion.

Risk Factors

Risk factors for a structural variant include a personal or family history of early-onset aortic aneurysm or dissection, unexplained arterial tortuosity, recurrent fractures, extreme joint hypermobility, characteristic skeletal features, congenital contractures, marked skin hyperextensibility, lens abnormalities, and multiple apparently unrelated connective tissue manifestations. Consanguinity and a history of affected individuals across successive generations may suggest a recessive or dominant inherited disorder, respectively. However, de novo rearrangements are also important and may occur without a prior family history.

Genomic features influence variant formation and detection. Low-copy repeats, segmental duplications, tandem repeats, transposable elements, and regions with high guanine-cytosine content can promote nonallelic homologous recombination or replication-based rearrangement. Previous negative testing should not be interpreted as excluding a genetic diagnosis when the phenotype is compelling, particularly if testing used limited panels, array methods without sequence resolution, or short-read data with inadequate coverage. Long-read testing may be considered when a known familial variant is structurally complex, when conventional copy-number analysis is inconclusive, or when clinical findings strongly suggest a disorder despite negative routine sequencing.

Clinical Features

Clinical presentation varies according to the affected gene and the mechanism of the structural change. Patients with heritable aortopathy may develop aortic root enlargement, aneurysm in other arterial territories, arterial tortuosity, or dissection at a relatively young age. Features of syndromic disease can include arachnodactyly, pectus deformity, scoliosis, joint laxity, contractures, translucent or fragile skin, easy bruising, and characteristic facial findings. Skeletal phenotypes may involve short stature, limb deformity, dentin abnormalities, vertebral compression, and recurrent fractures.

Phenotypic overlap is substantial. A person with a pathogenic variant may have few external signs but carry significant vascular risk, whereas another individual may have severe musculoskeletal disease without major cardiovascular involvement. This variability makes molecular clarification especially useful. Precise structural variant characterization can help distinguish alleles associated with haploinsufficiency from those causing dominant-negative effects and can support risk assessment for relatives who appear clinically unaffected.

Diagnosis

Diagnostic evaluation should integrate detailed personal and family history, physical examination, cardiovascular imaging, ophthalmologic assessment, skeletal radiography when indicated, and molecular testing. Initial laboratory strategy depends on the phenotype and local resources. Multigene panels and exome sequencing are useful for many patients, while genome sequencing offers broader assessment of noncoding and structural variation. Copy-number analysis, chromosomal microarray, multiplex ligation-dependent probe amplification, and targeted breakpoint testing remain valuable in selected circumstances.

Long-read sequencing can identify large deletions and duplications, balanced rearrangements, inversions, repeat-associated events, mobile-element insertions, and complex combinations of variants in a single assay. It can also provide phasing, demonstrating whether two variants occur on the same allele or on different chromosomes. This distinction may alter interpretation in recessive disorders and clarify the molecular basis of apparent compound heterozygosity. Methylation-aware or native-DNA approaches may add epigenetic information in selected diseases, although clinical validation is still developing.

Interpretation requires confirmation of read-level evidence, assessment of breakpoint quality, evaluation of population frequency, prediction of transcript consequences, and correlation with phenotype and inheritance. Classification should follow established variant interpretation frameworks, with explicit distinction between pathogenic, likely pathogenic, uncertain, and benign findings. A technically visible rearrangement is not automatically disease-causing; functional evidence, segregation, RNA studies, or orthogonal confirmation may be required, particularly for regulatory or intronic variants.

Treatment & Management

Management remains phenotype driven, but molecular diagnosis can substantially improve its precision. Patients with heritable aortopathy may require scheduled echocardiography, cross-sectional vascular imaging, blood pressure control, and individualized thresholds for prophylactic surgery. Pharmacological treatment commonly includes agents that reduce hemodynamic stress, selected according to cardiovascular status and specialist guidance. Individuals with significant vascular Ehlers-Danlos features require careful procedural planning because tissue fragility may increase bleeding and surgical risk.

Bone fragility disorders require fracture prevention, physical therapy, fall-risk reduction, dental care, orthopedic assessment, and, when appropriate, pharmacological treatment under specialist supervision. Musculoskeletal manifestations of hypermobility spectrum disorders may benefit from structured rehabilitation rather than repeated invasive procedures. Genetic counseling should address inheritance, reproductive options, limitations of testing, and the possibility of variable expressivity. Cascade testing is particularly important when a pathogenic structural variant confers risk of aortic disease or severe skeletal complications.

Recent Advances / Emerging Therapies

Recent progress includes higher-accuracy long-read chemistry, adaptive sequencing, improved basecalling, and integrated algorithms that combine structural variant detection with small-variant analysis. Assemblies generated from long reads can resolve previously inaccessible genomic regions and may identify disease-associated haplotypes that are invisible to reference-based short-read analysis. Hybrid workflows, in which long reads are combined with high-accuracy short reads, optical mapping, RNA sequencing, or methylation profiling, may improve sensitivity and functional interpretation.

Emerging therapeutic research is exploring allele-specific silencing, antisense oligonucleotides, genome editing, RNA correction, and strategies to enhance extracellular matrix stability. These approaches remain investigational for most connective tissue disorders, and their applicability depends on precise knowledge of the pathogenic mechanism. Structural variant resolution may therefore become increasingly important for selecting patients for molecular therapies and monitoring treatment response. Nonetheless, clinical implementation requires rigorous validation, standardized reporting, long-term outcome data, and careful assessment of off-target effects and germline implications.

Guideline Recommendations

Current clinical practice supports genetic evaluation for patients with syndromic features, early-onset thoracic aortic disease, a strong family history, unexplained arterial events, or characteristic skeletal and skin findings. Testing should be performed with informed consent and accompanied by pretest and post-test counseling. A negative result from a conventional panel should not end evaluation when clinical suspicion remains high. Referral to a clinical geneticist or a multidisciplinary inherited connective tissue disease service is appropriate for unresolved cases.

Long-read sequencing should be selected according to the clinical question, laboratory capability, and availability of validated interpretation. It is especially reasonable when a suspected disorder involves repetitive or structurally complex regions, when prior testing detected an incompletely characterized copy-number change, or when standard sequencing failed to explain a highly specific phenotype. Results should be integrated with imaging and clinical surveillance rather than used as a substitute for established risk management. Laboratories should document assay limitations, coverage gaps, quality metrics, confirmation procedures, and policies for reporting secondary findings.

Conclusion

Long-read sequencing is expanding the diagnostic landscape for human connective tissue disorders by revealing structural variants that are difficult to detect or interpret with conventional methods. Its ability to span repetitive DNA, resolve breakpoints, phase alleles, and characterize complex rearrangements is particularly relevant to heritable aortopathies, Ehlers-Danlos syndromes, osteogenesis imperfecta, and related extracellular matrix disorders. The greatest clinical value arises when genomic findings are combined with careful phenotyping, cardiovascular and skeletal surveillance, family studies, and multidisciplinary counseling. Continued improvements in accuracy, affordability, standards for variant interpretation, and integration with transcriptomic and epigenomic data should strengthen the role of long-read sequencing in routine care. For appropriately selected patients, it offers a practical route from unexplained disease to more precise diagnosis, prevention, and individualized management.